High-resolution contrast-enhanced, susceptibility-weighted MR imaging at 3T in patients with brain tumors: correlation with positron-emission tomography and histopathologic findings.
OBJECTIVE
The purpose of this work was to demonstrate susceptibility effects (SusE) in various types of brain tumors with 3T high-resolution (HR)-contrast-enhanced (CE)-susceptibility-weighted (SW)-MR imaging and to correlate SusE with positron-emission tomography (PET) and histopathology.


METHODS
Eighteen patients with brain tumors, scheduled for biopsy or tumor extirpation, underwent high-field (3T) MR imaging. In all of the patients, an axial T1-spin-echo (SE) sequence and an HR-SW imaging sequence before and after IV application of a standard dose of contrast agent (MultiHance) was obtained. Seven patients preoperatively underwent PET. The frequency and formation of intralesional SusE in all of the images were evaluated and correlated with tumor grade as determined by PET and histopathology. Direct correlation of SusE and histopathologic specimens was performed in 6 patients. Contrast enhancement of the lesions was assessed in both sequences.


RESULTS
High-grade lesions demonstrated either high or medium frequency of SusE in 90% of the patients. Low-grade lesions demonstrated low frequency of SusE or no SusE. Correlation between intralesional frequency of SusE and histopathologic, as well as PET, tumor grading was statistically significant. Contrast enhancement was equally visible in both SW and SE sequences. Side-to-side comparison of tumor areas with high frequency of SusE and histopathology revealed that intralesional SusE reflected conglomerates of increased tumor microvascularity.


CONCLUSIONS
3T HR-CE-SW-MR imaging shows both intratumoral SusE not visible with standard MR imaging and contrast enhancement visible with standard MR imaging. Because frequency of intratumoral SusE correlates with tumor grade as determined by PET and histopathology, this novel technique is a promising tool for noninvasive differentiation of low-grade from high-grade brain tumors and for determination of an optimal area of biopsy for accurate tumor grading.
Pinker
K
K
MR Centre of Excellence, Department of Radiology, Medical University Vienna, Vienna, Austria.
Noebauer-Huhmann
I M
IM
Stavrou
I
I
Hoeftberger
R
R
Szomolanyi
P
P
Karanikas
G
G
Weber
M
M
Stadlbauer
A
A
Knosp
E
E
Friedrich
K
K
Trattnig
S
S
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000473:pathology; D003287:Contrast Media; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives*; D008875:Middle Aged; D009942:Organometallic Compounds; D049268:Positron-Emission Tomography / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013223:Statistics as Topic
D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine
Cancer. 1985 Sep 1;56(5):1106-11
2990664
Radiology. 2006 Mar;238(3):958-69
16424238
Invest Radiol. 2006 Mar;41(3):249-55
16481907
J Magn Reson Imaging. 2005 Oct;22(4):439-50
16163700
Neuroradiology. 2002 Aug;44(8):656-66
12185543
J Magn Reson Imaging. 2006 Jul;24(1):41-51
16755540
J Clin Oncol. 2006 Mar 10;24(8):1273-80
16525182
Eur Radiol. 2006 Jun;16(6):1280-7
16508769
MAGMA. 1998 Aug;6(1):62-9
9794291
Radiology. 1997 Feb;202(2):511-6
9015082
Zentralbl Neurochir. 2006 May;67(2):55-66
16673237
AJNR Am J Neuroradiol. 2005 Apr;26(4):736-42
15814914
Expert Rev Neurother. 2005 Nov;5(6 Suppl):S33-9
16274269
J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
11895036
J Radiol. 2004 Nov;85(11):1901-8
15602412
Invest Radiol. 2003 Jul;38(7):409-14
12821854
Semin Radiat Oncol. 1998 Jul;8(3):197-207
9634496
Radiology. 1997 Jul;204(1):272-7
9205259
Curr Treat Options Oncol. 2001 Dec;2(6):495-506
12057095
Invest Radiol. 2003 Jul;38(7):415-22
12821855
Magn Reson Med. 2004 Sep;52(3):612-8
15334582
Invest Radiol. 1999 Jun;34(6):427-34
10353036
AJNR Am J Neuroradiol. 2004 May;25(5):756-60
15140714
Neuroradiology. 2001 May;43(5):364-9
11396739
NMR Biomed. 2001 Nov-Dec;14(7-8):453-67
11746938
J Comput Assist Tomogr. 2000 Nov-Dec;24(6):949-57
11105717
J Magn Reson Imaging. 1999 Aug;10(2):118-23
10441013
NMR Biomed. 2001 Nov-Dec;14(7-8):478-83
11746940
AJNR Am J Neuroradiol. 2002 Oct;23(9):1553-6
12372746
AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98
14625221
Rofo. 2005 Aug;177(8):1065-9
16021537